Entities / Company
National Comprehensive Cancer Network.
non-profit organization in the USA
- Reports this week
- 7
- Active events
- 2
- Connections
- 29
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
-
The American Cancer Society and National Comprehensive Cancer Network published findings in a journal regarding cancer in the United States.Well supported7 reports
-
Updated guidelines from the National Comprehensive Cancer Network are driving the adoption and frequency of clonoSEQ testing, with Medicare coverage providing a foundation for reimbursement.Some support2 reports
Earlier this month
One to three months ago
-
The FDA approved a drug for advanced breast cancer patients, and the recommended regimens were designated as preferred Category 1 options by the National Comprehensive Cancer Network.Some support3 reports
-
Guardant Health reported results from Palo Alto on July 31, 2025. Shield MCD received Breakthrough Device Designation from the FDA and was included in NCCN colorectal cancer screening guidelines.Well supported4 reports3 developments inside
-
PEDMARK therapy received recognition from the National Comprehensive Cancer Network (NCCN) on August 11, alongside Fennec evaluating partnerships in Japan.Some support1 report
-
The European Institute of Oncology and the National Comprehensive Cancer Network are involved in a recent development.Some support1 report
Gone quiet
No new reports in 90+ days-
Guidelines reflect growing alignment among key organizations, involving the National Comprehensive Cancer Network and Infectious Diseases Society of America.Some support1 report
-
ImmunityBio initiated Phase 1 trials for NSCLC in US sites, while the FDA remained supportive of new data and the company sought guideline expansion from NCCN.Some support1 report
-
Taletrectinib was added to NCCN guidelines and selected as a preferred agent for cancer treatment.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around National Comprehensive Cancer Network this week
News at the entities that move National Comprehensive Cancer Network most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves National Comprehensive Cancer Network
-
Guardant Health StructuralEVANS welcomed Guardant Health as a sponsor for a coalition planning events across North America.Moves National Comprehensive Cancer Network
-
Gilead Sciences OperationalRequired regulatory filings regarding institutional holdings were made by Gilead Sciences, Inc. with the Securities and Exchange Commission on June 11, 2026.Moves National Comprehensive Cancer Network
-
American Cancer Society Mentioned togetherThe American Cancer Society is advocating for pediatric cancer research funding in partnership with Rutland County.Moves National Comprehensive Cancer Network
Connections
The 7 strongest of 29, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Guardant Health Structural
NCCN formally included Guardant Health's Shield test in its colorectal cancer screening guidelines.
-
FDA Structural
FDA approvals serve as the necessary regulatory basis upon which the National Comprehensive Cancer Network builds its clinical treatment guidelines.
-
Gilead Sciences Operational
NCC review directly influences the preferred status of Gilead's drugs.
-
Evans Structural
NCCN formally recognized Evans' PEDMARK therapy, indicating structural validation of the company's product.
-
American Cancer Society Mentioned together
Both entities were mentioned in a journal publication regarding cancer findings.
-
European Institute of Oncology Structural
The European Institute of Oncology is formally affiliated with the National Comprehensive Cancer Network.
-
ImmunityBio Operational
ImmunityBio actively engages the National Comprehensive Cancer Network to seek guideline expansion and operates within its clinical context.
History
Events by the month they beganSeptember 2026
2 eventsAugust 2026
4 events- The American Cancer Society and National Comprehensive Cancer Network published findings in a journal regarding cancer in the United States.
- The FDA approved a drug for advanced breast cancer patients, and the recommended regimens were designated as preferred Category 1 options by the National Comprehensive Cancer Network.
- PEDMARK therapy received recognition from the National Comprehensive Cancer Network (NCCN) on August 11, alongside Fennec evaluating partnerships in Japan.
- The European Institute of Oncology and the National Comprehensive Cancer Network are involved in a recent development.
June 2026
4 events- Guardant Health reported results from Palo Alto on July 31, 2025. Shield MCD received Breakthrough Device Designation from the FDA and was included in NCCN colorectal cancer screening guidelines.
- Guidelines reflect growing alignment among key organizations, involving the National Comprehensive Cancer Network and Infectious Diseases Society of America.
- ImmunityBio initiated Phase 1 trials for NSCLC in US sites, while the FDA remained supportive of new data and the company sought guideline expansion from NCCN.
- Taletrectinib was added to NCCN guidelines and selected as a preferred agent for cancer treatment.